Physician profile
Daniel A Scher
NPI 1912946583
$3,598.84
in general payments reported to CMS, 2019-2025
29 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 80% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $85.22 · 2021: $205 · 2022: $348 · 2023: $535 · 2024: $1,141 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,324 · Travel and Lodging: $383.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,324.42 |
| Travel and Lodging | $383.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $669.28 | 2022-2025 | |
| Aerin Medical INC. | $507.88 | 2022-2025 | |
| Biosense Webster, INC. | $383.12 | 2024 | Thermocool Sf |
| Glaxosmithkline, LLC. | $363.63 | 2019-2025 | Nucala |
| Optinose US, INC. | $289.37 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $277.42 | 2022-2025 | Dupixent |
| Stryker Corporation | $192.21 | 2019-2022 | |
| Csl Behring | $168.65 | 2020-2025 | Haegarda, Hizentra, Andembry |
| Kaleo, INC. | $87.55 | 2022-2024 | Auvi-Q |
| Intersect Ent, INC. | $68.63 | 2020-2021 | |
| Inspire Medical Systems, INC. | $61.08 | 2024-2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $60.18 | 2021-2024 | Cuvitru, Takhzyro |
| Leo Pharma INC. | $59.42 | 2022 | |
| Merck Sharp & Dohme LLC | $51.08 | 2021-2023 | Verquvo |
| Shockwave Medical, INC | $50.14 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $46.91 | 2023-2024 | Ryaltris |
| Novartis Pharmaceuticals Corporation | $34.19 | 2025 | |
| Aytu Biopharma, INC. | $33.20 | 2025 | |
| Olympus America INC. | $29.87 | 2019 | |
| Medtronic, INC. | $26.14 | 2025 | Propel |
| Travere Therapeutics, INC. | $19.94 | 2019 | |
| Lilly USA, LLC | $19.64 | 2025 | Zepbound |
| Blueprint Medicines Corporation | $18.65 | 2023 | Ayvakit |
| Boston Scientific Corporation | $15.79 | 2019 | |
| Aimmune Therapeutics, INC. | $14.92 | 2022 | |
| Grifols USA, LLC | $14.35 | 2022 | |
| Biocryst US Sales Co., LLC | $14.10 | 2024 | Orladeyo |
| Pharming Healthcare, INC. | $12.50 | 2019 | |
| Glenmark Therapeutics INC. | $9.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Scher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.